Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 625

1.

Human Endogenous Retroviruses: Residues of Ancient Times Are Differentially Expressed in Crohn's Disease.

Klag T, Courth L, Ostaff MJ, Ott G, Stange EF, Malek NP, Seifarth W, Wehkamp J.

Inflamm Intest Dis. 2019 Feb;3(3):125-137. doi: 10.1159/000494026. Epub 2018 Nov 21.

2.

Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.

Heavican TB, Bouska A, Yu J, Lone W, Amador C, Gong Q, Zhang W, Li Y, Dave BJ, Nairismägi ML, Greiner TC, Vose J, Weisenburger DD, Lachel C, Wang C, Fu K, Stevens JM, Lim ST, Ong CK, Gascoyne RD, Missiaglia E, Lemonnier F, Haioun C, Hartmann S, Pedersen MB, Laginestra MA, Wilcox RA, Teh BT, Yoshida N, Ohshima K, Seto M, Rosenwald A, Ott G, Campo E, Rimsza LM, Jaffe ES, Braziel RM, d'Amore F, Inghirami G, Bertoni F, de Leval L, Gaulard P, Staudt LM, McKeithan TW, Pileri S, Chan WC, Iqbal J.

Blood. 2019 Feb 19. pii: blood-2018-09-872549. doi: 10.1182/blood-2018-09-872549. [Epub ahead of print]

PMID:
30782609
3.

The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma.

Wagener R, Seufert J, Raimondi F, Bens S, Kleinheinz K, Nagel I, Altmüller J, Thiele H, Hübschmann D, Kohler CW, Nürnberg P, Au-Yeung R, Burkhardt B, Horn H, Leoncini L, Jaffe ES, Ott G, Rymkiewicz G, Schlesner M, Russell RB, Klapper W, Siebert R.

Blood. 2019 Feb 28;133(9):962-966. doi: 10.1182/blood-2018-07-864025. Epub 2018 Dec 19.

PMID:
30567752
4.

Differential expression of long non-coding RNAs are related to proliferation and histological diversity in follicular lymphomas.

Roisman A, Castellano G, Navarro A, Gonzalez-Farre B, Pérez-Galan P, Esteve-Codina A, Dabad M, Heath S, Gut M, Bosio M, Bellot P, Salembier P, Oliveras A, Slavutsky I, Magnano L, Horn H, Rosenwald A, Ott G, Aymerich M, López-Guillermo A, Jares P, Martín-Subero JI, Campo E, Hernández L.

Br J Haematol. 2019 Feb;184(3):373-383. doi: 10.1111/bjh.15656. Epub 2018 Nov 22.

PMID:
30565652
5.

CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma.

Martín-Garcia D, Navarro A, Valdés-Mas R, Clot G, Gutiérrez-Abril J, Prieto M, Ribera-Cortada I, Woroniecka R, Rymkiewicz G, Bens S, de Leval L, Rosenwald A, Ferry JA, Hsi ED, Fu K, Delabie J, Weisenburger D, de Jong D, Climent F, O'Connor SJ, Swerdlow SH, Torrents D, Beltran S, Espinet B, González-Farré B, Veloza L, Costa D, Matutes E, Siebert R, Ott G, Quintanilla-Martinez L, Jaffe ES, López-Otín C, Salaverria I, Puente XS, Campo E, Beà S.

Blood. 2019 Feb 28;133(9):940-951. doi: 10.1182/blood-2018-07-862151. Epub 2018 Dec 11.

PMID:
30538135
6.

Chromatin conformation analysis of primary patient tissue using a low input Hi-C method.

Díaz N, Kruse K, Erdmann T, Staiger AM, Ott G, Lenz G, Vaquerizas JM.

Nat Commun. 2018 Nov 29;9(1):4938. doi: 10.1038/s41467-018-06961-0.

7.

Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens.

Mottok A, Wright G, Rosenwald A, Ott G, Ramsower C, Campo E, Braziel RM, Delabie J, Weisenburger DD, Song JY, Chan WC, Cook JR, Fu K, Greiner T, Smeland E, Holte H, Savage KJ, Glinsmann-Gibson BJ, Gascoyne RD, Staudt LM, Jaffe ES, Connors JM, Scott DW, Steidl C, Rimsza LM.

Blood. 2018 Nov 29;132(22):2401-2405. doi: 10.1182/blood-2018-05-851154. Epub 2018 Sep 26.

PMID:
30257882
8.

Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA.

Heine S, Kleih M, Giménez N, Böpple K, Ott G, Colomer D, Aulitzky WE, van der Kuip H, Silkenstedt E.

J Hematol Oncol. 2018 Sep 4;11(1):112. doi: 10.1186/s13045-018-0657-6.

9.

Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles.

Hellmuth JC, Louissaint A Jr, Szczepanowski M, Haebe S, Pastore A, Alig S, Staiger AM, Hartmann S, Kridel R, Ducar MD, Koch P, Dreyling M, Hansmann ML, Ott G, Rosenwald A, Gascoyne RD, Weinstock DM, Hiddemann W, Klapper W, Weigert O.

Blood. 2018 Oct 18;132(16):1695-1702. doi: 10.1182/blood-2018-03-837252. Epub 2018 Aug 20.

PMID:
30126979
10.

Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network.

Rauert-Wunderlich H, Mottok A, Scott DW, Rimsza LM, Ott G, Klapper W, Unterhalt M, Kluin-Nelemans HC, Hermine O, Hartmann S, Thorns C, Rymkiewicz G, Holte H, Dreyling M, Hoster E, Rosenwald A.

Br J Haematol. 2019 Feb;184(4):616-624. doi: 10.1111/bjh.15519. Epub 2018 Aug 10.

PMID:
30095158
11.

[Revised version of the 4th edition of the WHO classification of malignant lymphomas : What is new?]

Ott G, Klapper W, Feller AC, Hansmann ML, Möller P, Stein H, Rosenwald A, Fend F.

Pathologe. 2019 Mar;40(2):157-168. doi: 10.1007/s00292-018-0456-4. Review. German.

PMID:
30019203
12.

Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.

Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Pedamallu CS, Livitz D, Rosebrock D, Rosenberg M, Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub TR, Beroukhim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler M, Pfreundschuh M, Trümper L, Getz G, Shipp MA.

Nat Med. 2018 Aug;24(8):1290-1291. doi: 10.1038/s41591-018-0097-4.

PMID:
29955182
13.

Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.

Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Pedamallu CS, Livitz D, Rosebrock D, Rosenberg M, Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub TR, Beroukhim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler M, Pfreundschuh M, Trümper L, Getz G, Shipp MA.

Nat Med. 2018 Aug;24(8):1292. doi: 10.1038/s41591-018-0098-3.

PMID:
29955181
14.

A multiprotein supercomplex controlling oncogenic signalling in lymphoma.

Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M, Shaffer AL 3rd, Ceribelli M, Wang JQ, Schmitz R, Nakagawa M, Bachy E, Huang DW, Ji Y, Chen L, Yang Y, Zhao H, Yu X, Xu W, Palisoc MM, Valadez RR, Davies-Hill T, Wilson WH, Chan WC, Jaffe ES, Gascoyne RD, Campo E, Rosenwald A, Ott G, Delabie J, Rimsza LM, Rodriguez FJ, Estephan F, Holdhoff M, Kruhlak MJ, Hewitt SM, Thomas CJ, Pittaluga S, Oellerich T, Staudt LM.

Nature. 2018 Aug;560(7718):387-391. doi: 10.1038/s41586-018-0290-0. Epub 2018 Jun 20.

15.

Histiocytic necrotising lymphadenitis identical to Kikuchi-Fujimoto disease in CNS lupus.

Stefanou MI, Ott G, Ziemann U, Mengel A.

BMJ Case Rep. 2018 Jun 8;2018. pii: bcr-2018-225668. doi: 10.1136/bcr-2018-225668. No abstract available.

PMID:
29884722
16.

A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome.

Clot G, Jares P, Giné E, Navarro A, Royo C, Pinyol M, Martín-Garcia D, Demajo S, Espinet B, Salar A, Ferrer A, Muntañola A, Aymerich M, Rauert-Wunderlich H, Jaffe ES, Connors JM, Gascoyne RD, Delabie J, López-Guillermo A, Ott G, Wright GW, Staudt LM, Rosenwald A, Scott DW, Rimsza LM, Beà S, Campo E.

Blood. 2018 Jul 26;132(4):413-422. doi: 10.1182/blood-2018-03-838136. Epub 2018 May 16.

PMID:
29769262
17.

A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy.

Mönch D, Bode-Erdmann S, Kalla J, Sträter J, Schwänen C, Falkenstern-Ge R, Klumpp S, Friedel G, Ott G, Kalla C.

Oncotarget. 2018 Apr 17;9(29):20781-20794. doi: 10.18632/oncotarget.25111. eCollection 2018 Apr 17.

18.

Round-robin test for the cell-of-origin classification of diffuse large B-cell lymphoma-a feasibility study using full slide staining.

Reinke S, Richter J, Fend F, Feller A, Hansmann ML, Hüttl K, Oschlies I, Ott G, Möller P, Rosenwald A, Stein H, Altenbuchinger M, Spang R, Klapper W.

Virchows Arch. 2018 Sep;473(3):341-349. doi: 10.1007/s00428-018-2367-4. Epub 2018 May 5.

PMID:
29730836
19.

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.

Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Pedamallu CS, Livitz D, Rosebrock D, Rosenberg M, Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub TR, Beroukhim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler M, Pfreundschuh M, Trümper L, Getz G, Shipp MA.

Nat Med. 2018 May;24(5):679-690. doi: 10.1038/s41591-018-0016-8. Epub 2018 Apr 30. Erratum in: Nat Med. 2018 Aug;24(8):1292. Nat Med. 2018 Aug;24(8):1290-1291.

PMID:
29713087
20.

[Aggressive B‑cell lymphomas : Recommendations from the German Panel of Reference Pathologists in the Competence Network on Malignant Lymphomas on diagnostic procedures according to the current WHO classification, update 2017].

Klapper W, Fend F, Feller A, Hansmann ML, Möller P, Stein H, Rosenwald A, Ott G.

Pathologe. 2019 Mar;40(2):152-156. doi: 10.1007/s00292-018-0440-z. Review. German.

PMID:
29666909
21.

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.

Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, Tay Kuang Wei K, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson WH, Staudt LM.

N Engl J Med. 2018 Apr 12;378(15):1396-1407. doi: 10.1056/NEJMoa1801445.

22.

Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2.

Horn H, Kohler C, Witzig R, Kreuz M, Leich E, Klapper W, Hummel M, Loeffler M, Trümper L, Spang R, Rosenwald A, Ott G; Molecular Mechanisms in Malignant Lymphomas (MMML) Network Project.

Haematologica. 2018 Jul;103(7):1182-1190. doi: 10.3324/haematol.2017.181024. Epub 2018 Mar 22.

23.

Is Mistletoe Treatment Beneficial in Invasive Breast Cancer? A New Approach to an Unresolved Problem.

Fritz P, Dippon J, Müller S, Goletz S, Trautmann C, Pappas X, Ott G, Brauch H, Schwab M, Winter S, Mürdter T, Brinkmann F, Faisst S, Rössle S, Gerteis A, Friedel G.

Anticancer Res. 2018 Mar;38(3):1585-1593.

PMID:
29491089
24.

High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.

Scott DW, King RL, Staiger AM, Ben-Neriah S, Jiang A, Horn H, Mottok A, Farinha P, Slack GW, Ennishi D, Schmitz N, Pfreundschuh M, Nowakowski GS, Kahl BS, Connors JM, Gascoyne RD, Ott G, Macon WR, Rosenwald A.

Blood. 2018 May 3;131(18):2060-2064. doi: 10.1182/blood-2017-12-820605. Epub 2018 Feb 23.

PMID:
29475959
25.

The exomic landscape of t(14;18)-negative diffuse follicular lymphoma with 1p36 deletion.

Zamò A, Pischimarov J, Horn H, Ott G, Rosenwald A, Leich E.

Br J Haematol. 2018 Feb;180(3):391-394. doi: 10.1111/bjh.15041. Epub 2017 Nov 28.

PMID:
29193015
26.

Increased cFLIP expression in thymic epithelial tumors blocks autophagy via NF-κB signalling.

Belharazem D, Grass A, Paul C, Vitacolonna M, Schalke B, Rieker RJ, Körner D, Jungebluth P, Simon-Keller K, Hohenberger P, Roessner EM, Wiebe K, Gräter T, Kyriss T, Ott G, Geserick P, Leverkus M, Ströbel P, Marx A.

Oncotarget. 2017 Feb 6;8(52):89580-89594. doi: 10.18632/oncotarget.15929. eCollection 2017 Oct 27.

27.

Ultraviolet germicidal efficacy as a function of pulsed radiation parameters studied by spore film dosimetry.

Bauer S, Holtschmidt H, Ott G.

J Photochem Photobiol B. 2018 Jan;178:69-75. doi: 10.1016/j.jphotobiol.2017.10.027. Epub 2017 Oct 28.

PMID:
29125984
28.

FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.

Mottok A, Jurinovic V, Farinha P, Rosenwald A, Leich E, Ott G, Horn H, Klapper W, Boesl M, Hiddemann W, Steidl C, Connors JM, Sehn LH, Gascoyne RD, Hoster E, Weigert O, Kridel R.

Blood. 2018 Jan 11;131(2):226-235. doi: 10.1182/blood-2017-08-799080. Epub 2017 Nov 9.

29.

Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment.

Mirza AN, Fry MA, Urman NM, Atwood SX, Roffey J, Ott GR, Chen B, Lee A, Brown AS, Aasi SZ, Hollmig T, Ator MA, Dorsey BD, Ruggeri BR, Zificsak CA, Sirota M, Tang JY, Butte A, Epstein E, Sarin KY, Oro AE.

JCI Insight. 2017 Nov 2;2(21). pii: 97071. doi: 10.1172/jci.insight.97071.

30.

Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.

Rudelius M, Rosenfeldt MT, Leich E, Rauert-Wunderlich H, Solimando AG, Beilhack A, Ott G, Rosenwald A.

Haematologica. 2018 Jan;103(1):116-125. doi: 10.3324/haematol.2017.177162. Epub 2017 Oct 27.

31.

Mathematical Modeling of Optical Radiation Emission as a Function of Welding Power during Gas Shielded Metal Arc Welding.

Bauer S, Janßen M, Schmitz M, Ott G.

Health Phys. 2017 Nov;113(5):335-346. doi: 10.1097/HP.0000000000000709.

PMID:
28961581
32.

Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC.

Paul U, Richter J, Stuhlmann-Laiesz C, Kreuz M, Nagel I, Horn H, Staiger AM, Aukema SM, Hummel M, Ott G, Spang R, Rosenwald A, Feller AC, Cogliatti S, Stein H, Hansmann ML, Moller P, Szczepanowski M, Burkhardt B, Pfreundschuh M, Schmitz N, Loeffler M, Trümper L, Siebert R, Klapper W.

Leuk Lymphoma. 2018 May;59(5):1213-1221. doi: 10.1080/10428194.2017.1365851. Epub 2017 Aug 25.

PMID:
28838257
33.

Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing.

Zamò A, Pischimarov J, Schlesner M, Rosenstiel P, Bomben R, Horn H, Grieb T, Nedeva T, López C, Haake A, Richter J, Trümper L, Lawerenz C, Klapper W, Möller P, Hummel M, Lenze D, Szczepanowski M, Flossbach L, Schreder M, Gattei V, Ott G, Siebert R, Rosenwald A, Leich E.

Leukemia. 2018 Mar;32(3):685-693. doi: 10.1038/leu.2017.270. Epub 2017 Aug 21.

PMID:
28824170
34.

Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets.

Bouska A, Bi C, Lone W, Zhang W, Kedwaii A, Heavican T, Lachel CM, Yu J, Ferro R, Eldorghamy N, Greiner TC, Vose J, Weisenburger DD, Gascoyne RD, Rosenwald A, Ott G, Campo E, Rimsza LM, Jaffe ES, Braziel RM, Siebert R, Miles RR, Dave S, Reddy A, Delabie J, Staudt LM, Song JY, McKeithan TW, Fu K, Green M, Chan WC, Iqbal J.

Blood. 2017 Oct 19;130(16):1819-1831. doi: 10.1182/blood-2017-02-767335. Epub 2017 Aug 11.

35.

Pyrrolo[2,1-f][1,2,4]triazines: From C-nucleosides to kinases and back again, the remarkable journey of a versatile nitrogen heterocycle.

Ott GR, Favor DA.

Bioorg Med Chem Lett. 2017 Sep 15;27(18):4238-4246. doi: 10.1016/j.bmcl.2017.07.073. Epub 2017 Jul 30. Review.

PMID:
28801135
37.

TP53 mutation and survival in aggressive B cell lymphoma.

Zenz T, Kreuz M, Fuge M, Klapper W, Horn H, Staiger AM, Winter D, Helfrich H, Huellein J, Hansmann ML, Stein H, Feller A, Möller P, Schmitz N, Trümper L, Loeffler M, Siebert R, Rosenwald A, Ott G, Pfreundschuh M, Stilgenbauer S; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Int J Cancer. 2017 Oct 1;141(7):1381-1388. doi: 10.1002/ijc.30838. Epub 2017 Jun 26.

38.

Burkitt lymphoma and diffuse large B-cell lymphoma: a unique case of a composite lymphoma of different clonal origin.

Höring E, Staiger AM, Lenze D, Horn H, Vöhringer M, Steurer W, Aulitzky WE, Ott G.

Leuk Lymphoma. 2018 Jan;59(1):249-252. doi: 10.1080/10428194.2017.1330469. Epub 2017 Jun 5. No abstract available.

PMID:
28583033
39.

Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.

Leu K, Ott GA, Lai A, Nghiemphu PL, Pope WB, Yong WH, Liau LM, Cloughesy TF, Ellingson BM.

J Neurooncol. 2017 Aug;134(1):177-188. doi: 10.1007/s11060-017-2506-9. Epub 2017 May 25.

40.

Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation.

Schmidt J, Ramis-Zaldivar JE, Nadeu F, Gonzalez-Farre B, Navarro A, Egan C, Montes-Mojarro IA, Marafioti T, Cabeçadas J, van der Walt J, Dojcinov S, Rosenwald A, Ott G, Bonzheim I, Fend F, Campo E, Jaffe ES, Salaverria I, Quintanilla-Martinez L.

Blood. 2017 Jul 20;130(3):323-327. doi: 10.1182/blood-2017-03-776278. Epub 2017 May 22.

41.

Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.

Staiger AM, Ziepert M, Horn H, Scott DW, Barth TFE, Bernd HW, Feller AC, Klapper W, Szczepanowski M, Hummel M, Stein H, Lenze D, Hansmann ML, Hartmann S, Möller P, Cogliatti S, Lenz G, Trümper L, Löffler M, Schmitz N, Pfreundschuh M, Rosenwald A, Ott G; German High-Grade Lymphoma Study Group.

J Clin Oncol. 2017 Aug 1;35(22):2515-2526. doi: 10.1200/JCO.2016.70.3660. Epub 2017 May 19.

PMID:
28525305
42.

Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.

Kühnl A, Cunningham D, Counsell N, Hawkes EA, Qian W, Smith P, Chadwick N, Lawrie A, Mouncey P, Jack A, Pocock C, Ardeshna KM, Radford J, McMillan A, Davies J, Turner D, Kruger A, Johnson PW, Gambell J, Rosenwald A, Ott G, Horn H, Ziepert M, Pfreundschuh M, Linch D.

Ann Oncol. 2017 Jul 1;28(7):1540-1546. doi: 10.1093/annonc/mdx128.

43.

Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma.

Höring E, Montraveta A, Heine S, Kleih M, Schaaf L, Vöhringer MC, Esteve-Arenys A, Roué G, Colomer D, Campo E, Ott G, Aulitzky WE, van der Kuip H.

Br J Haematol. 2017 May;177(4):557-561. doi: 10.1111/bjh.14571. Epub 2017 Mar 14.

PMID:
28295185
44.

New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies.

Scott DW, Abrisqueta P, Wright GW, Slack GW, Mottok A, Villa D, Jares P, Rauert-Wunderlich H, Royo C, Clot G, Pinyol M, Boyle M, Chan FC, Braziel RM, Chan WC, Weisenburger DD, Cook JR, Greiner TC, Fu K, Ott G, Delabie J, Smeland EB, Holte H, Jaffe ES, Steidl C, Connors JM, Gascoyne RD, Rosenwald A, Staudt LM, Campo E, Rimsza LM; Lymphoma/Leukemia Molecular Profiling Project.

J Clin Oncol. 2017 May 20;35(15):1668-1677. doi: 10.1200/JCO.2016.70.7901. Epub 2017 Mar 14.

45.

Surgical occlusion of the left atrial appendage and thromboembolic complications in patients with left ventricular assist devices.

Lewis RS, Wang L, Spinelli KJ, Ott GY, Abraham J.

J Heart Lung Transplant. 2017 May;36(5):586-588. doi: 10.1016/j.healun.2017.01.1297. Epub 2017 Jan 30. No abstract available.

PMID:
28215476
46.

Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.

Erdmann T, Klener P, Lynch JT, Grau M, Vočková P, Molinsky J, Tuskova D, Hudson K, Polanska UM, Grondine M, Mayo M, Dai B, Pfeifer M, Erdmann K, Schwammbach D, Zapukhlyak M, Staiger AM, Ott G, Berdel WE, Davies BR, Cruzalegui F, Trneny M, Lenz P, Barry ST, Lenz G.

Blood. 2017 Jul 20;130(3):310-322. doi: 10.1182/blood-2016-12-758599. Epub 2017 Feb 15.

47.

An analysis of the role of follicular lymphoma-associated fibroblasts to promote tumor cell viability following drug-induced apoptosis.

Staiger AM, Duppel J, Dengler MA, van der Kuip H, Vöhringer MC, Aulitzky WE, Rosenwald A, Ott G, Horn H.

Leuk Lymphoma. 2017 Aug;58(8):1922-1930. doi: 10.1080/10428194.2016.1263841. Epub 2016 Dec 6.

PMID:
27919179
48.

New targeted therapies for malignant lymphoma based on molecular heterogeneity.

Horn H, Staiger AM, Ott G.

Expert Rev Hematol. 2017 Jan;10(1):39-51. doi: 10.1080/17474086.2017.1268046. Epub 2016 Dec 12. Review.

PMID:
27918211
49.

B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma.

Dai B, Grau M, Juilland M, Klener P, Höring E, Molinsky J, Schimmack G, Aukema SM, Hoster E, Vogt N, Staiger AM, Erdmann T, Xu W, Erdmann K, Dzyuba N, Madle H, Berdel WE, Trneny M, Dreyling M, Jöhrens K, Lenz P, Rosenwald A, Siebert R, Tzankov A, Klapper W, Anagnostopoulos I, Krappmann D, Ott G, Thome M, Lenz G.

Blood. 2017 Jan 19;129(3):333-346. doi: 10.1182/blood-2016-05-718775. Epub 2016 Nov 18.

50.

Technically Extended MultiParameter Optimization (TEMPO): An Advanced Robust Scoring Scheme To Calculate Central Nervous System Druggability and Monitor Lead Optimization.

Ghose AK, Ott GR, Hudkins RL.

ACS Chem Neurosci. 2017 Jan 18;8(1):147-154. doi: 10.1021/acschemneuro.6b00273. Epub 2016 Oct 26.

Supplemental Content

Support Center